- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03579836
Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient With Pancreatic Cancer
A Single Center, Open-label, Non-comparative, Phase I/II Clinical Trial to Assess the MTD, Safety and Efficacy of BEY1107 in Monotherapy and in Combination With Gemcitabine in Patient With Locally Advanced or Metastatic Pancreatic Cancer
Study Overview
Status
Intervention / Treatment
Detailed Description
The key purpose of the main part of the study is to assess the MTD, safety and efficacy of BEY1107 as monotherapy and combination therapy for locally advanced and/or metastatic pancreatic cancer. The main purpose of the safety lead-in (dose-finding) part of the study is to determine the safety and tolerability of BEY1107, to determine the MTD.
Patient will receive BEY1107 for 4 weeks in monotherapy for each cohort (administered in a 3-weeks-on / 1-week-off) during Phase I-1 trial.
At next stage, patient will receive BEY1107 with gemcitabine for 4weeks in phase I-2 trial.
Final stage, patient will receive BEY1107 with gemcitabine for 24weeks in phase II trial.
Blood samples will be collected for safety, pharmacokinetic and biomarker analysis. Archival of fresh biopsy tissue will also be collected for biomarker analysis.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Beyondbio Inc.
- Phone Number: +82-42-716-0020
- Email: clinicaltrials@beyondbio.co.kr
Study Locations
-
-
-
Seoul, Korea, Republic of
- Recruiting
- Yonsei University Health System Severance Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria :
- Histologically or Cytologically confirmed with pancreatic ductal adenocarcinoma or undifferentiated carcinoma of the pancreas
- At lease one measurable lesion according to RECIST v.1.1
- Eastern Cooperative Oncology Group (ECOG) 0,1 or 2
- Over 12 weeks of Life expectancy
- Adequate Bone marrow, Renal and Liver function at screening
Exclusion criteria :
- A patient who has treatment history with locally advanced and/or metastatic pancreatic cancer
- Major surgery history at screening
- Uncontrolled brain metastasis evidence
- Active bacterial infection patients
- Malignant tumor other than basal cell carcinoma, cervix carcinoma in situ and papillary thyroid cancer
- expected Pregnant or breast-feeding patients
- HIV, Active hepatitis B or C infection
- A patient who has hypersensitivity with BEY1107 or Gemcitabine
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase I-1 (#4 Cohort)
BEY1107 monotherapy, 4 Cohorts, 4 weeks (administered on a 3-week-on and 1-week-off)
|
Take orally with water once a day on a 3-weeks-on (21 days) continuously and 1-week-off (7 days) schedule.
|
Experimental: Phase I-2 (#3 Cohort)
BEY1107 in combination with Gemcitabine, 3 Cohorts, 4 weeks (administered on a 3-week-on and 1-week-off)
|
Take orally with water once a day on a 3-weeks-on (21 days) continuously and 1-week-off (7 days) schedule.
Administer 1,000 mg/m2 of Gemcitabine intravenously for 30 minutes on Day 1, 8, 15 and 1-week-off (7days) schedule.
|
Experimental: Phase II (#1 Cohort)
BEY1107 in combination with Gemcitabine, 6 Cycles / 24 weeks (administered on a 3-week-on and 1-week-off)
|
Take orally with water once a day on a 3-weeks-on (21 days) continuously and 1-week-off (7 days) schedule.
Administer 1,000 mg/m2 of Gemcitabine intravenously for 30 minutes on Day 1, 8, 15 and 1-week-off (7days) schedule.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
MTD & Safety assessment (Phase I)
|
DCR(Disease Control Rate) in combination therapy of BEY1107 and Gemcitabine (Phase II)
|
Secondary Outcome Measures
Outcome Measure |
---|
AUC in BEY1107 monotherapy and Gemcitabine combination (Phase I)
|
Cmax in BEY1107 monotherapy and Gemcitabine combination (Phase I)
|
DCR(Disease Control Rate) in BEY1107 monotherapy and Gemcitabine combination (Phase I)
|
ORR(Objective Response Rate) in BEY1107 and Gemcitabine combination (Phase II)
|
Number of subjects with Adverse events in BEY1107 and Gemcitabine combination (Phase II)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Pancreatic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Gemcitabine
Other Study ID Numbers
- BEY-2018-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Locally Advanced or Metastatic Pancreatic Cancer
-
Merck Sharp & Dohme LLCCompletedMetastatic or Locally Advanced Cancer
-
Gilead SciencesEverest MedicinesActive, not recruitingLocally Advanced or Metastatic Unresectable Urothelial CancerUnited States, Belgium, France, Spain, United Kingdom, Korea, Republic of, Czechia, Germany, Israel, China, Italy, Australia, Hong Kong, Taiwan, Portugal, Singapore, Croatia, Greece, Turkey, Sweden, Switzerland, Canada, Austria, Bulgaria and more
-
LetolabNot yet recruitingLocally Advanced or Metastatic CRC
-
Jiangsu Aosaikang Pharmaceutical Co., Ltd.CompletedLocally Advanced or Metastatic NSCLCChina
-
Jiangsu Aosaikang Pharmaceutical Co., Ltd.CompletedLocally Advanced or Metastatic NSCLCChina
-
Hospices Civils de LyonUnknownMetastatic or Locally Advanced Solid TumorsFrance
-
German Cancer Research CenterRecruiting
-
University Medical Center GroningenActive, not recruiting
-
Merck KGaA, Darmstadt, GermanyCompletedLocally Advanced or Metastatic Solid TumorsHungary
-
Taiho Oncology, Inc.Quintiles, Inc.; United BioSource, LLCCompletedLocally Advanced or Metastatic Pancreatic Cancer
Clinical Trials on BEY1107
-
BeyondBio Inc.RecruitingGlioblastoma MultiformeKorea, Republic of
-
BeyondBio Inc.RecruitingMetastatic Colorectal CancerKorea, Republic of